Cost vs. Quality: The Debate on Generic Medicines

Government-run Jan Aushadhi Kendras and chains like Generic Aadhaar offer medicines at a fraction of market prices, but pharma giants warn of quality risks. So, why is the All India Drug Action Network (AIDAN) advocating for the promotion of generic medicines despite quality concerns? How do pharmacy chains like Generic Aadhaar ensure the quality and affordability of their generic drugs? In the latest episode of The Morning Brief podcast, host Kiran Somvanshi delves into the heated debate over low-cost generic medicines with  Dr. Gopal Dabade from the Drug Action Forum, Arjun Deshpande of Generic Aadhaar, and ET's pharma expert Vikas Dandekar to explore the pros and cons of this pivotal policy move. Tune in! Check out other interesting episodes like: Polls on My Pod: The Adversaries in Punjab and Bengal, Polls on My Pod: Kashmir Finally Speaks Up!, Polls on My Pod: Ground Check on Delhi, Haryana Elections, Polls on My Pod: The Jal, Jangal, Zameen Struggle, Polls on My Pod: The Rae Bareli Fight & Gujarat’s Rajput Agitation, and more!You can follow our host Kiran Somvanshi on her social media: Twitter & LinkedinCatch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, JioSaavn,  Amazon Music and Google Podcasts.See omnystudio.com/listener for privacy information.